Page last updated: 2024-12-08

nicotinic acid adenine dinucleotide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nicotinic acid adenine dinucleotide: intermediate in the biosynthesis of NAD [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID165491
CHEBI ID18304
MeSH IDM0069745

Synonyms (11)

Synonym
DND ,
C00857
deamino-nad+
naadn
nicotinic acid adenine dinucleotide
deamido-nad+
DB04099
CHEBI:18304
adenosine 5'-{3-[1-(3-carboxypyridinio)-1,4-anhydro-d-ribitol-5-yl] dihydrogen diphosphate}
1-[(2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxymethyl]-3,4-dihydroxy-tetrahydrofuran-2-yl]pyridin-1-ium-3-carboxylic acid
Q28529688
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
nicotinic acid dinucleotide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (26)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Nicotinate and Nicotinamide Metabolism1434
Glutamate Metabolism2244
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
2-Hydroxyglutric Aciduria (D and L Form)2244
Succinic Semialdehyde Dehydrogenase Deficiency2244
NAD Biosynthesis520
NAD Salvage620
NAD Metabolism1435
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
Nicotinate D-ribonucleotide + ATP = Deamido-NAD+ + Pyrophosphate ( Nicotinate and Nicotinamide metabolism )24
Kynurenine pathway and links to cell senescence2024
NAD biosynthesis II (from tryptophan)024
pyridine nucleotide cycling017
NAD biosynthesis (from tryptophan)020
NAD biosynthesis I from aspartate020
NAD salvage pathway I017
NAD salvage pathway06
NAD biosynthesis II from tryptophan024
NAD+ biosynthetic pathways014
NAD biosynthesis I (from aspartate)419

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (14.71)18.7374
1990's7 (20.59)18.2507
2000's15 (44.12)29.6817
2010's6 (17.65)24.3611
2020's1 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (8.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]